Reprint notice: This is a short digest based on public FDA information. Copyright remains with the original publisher.
On August 6, 2026, the FDA granted accelerated approval to Tudriqev in combination with nivolumab for certain adults with advanced melanoma that progressed after anti-PD-1 therapy. Confirmatory trials are required.
Source：U.S. Food and Drug Administration · View original ↗